MAPT and amyloidosis: According to our results, in amyloid and p-tau–positive individuals, the use of PACC as the primary outcome is appropriate; however, in amyloid-positive individuals and amyloid-positive APOE ε4 carriers, a single neuropsychological test was more sensitive.